TrialThe Lancet. Oncology2010

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Jeffrey E Rubnitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.